Literature DB >> 10688917

Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells.

J Gong1, D Avigan, D Chen, Z Wu, S Koido, M Kashiwaba, D Kufe.   

Abstract

We have reported that fusions of murine dendritic cells (DCs) and murine carcinoma cells reverse unresponsiveness to tumor-associated antigens and induce the rejection of established metastases. In the present study, fusions were generated with primary human breast carcinoma cells and autologous DCs. Fusion cells coexpressed tumor-associated antigens and DC-derived costimulatory molecules. The fusion cells also retained the functional potency of DCs and stimulated autologous T cell proliferation. Significantly, the results show that autologous T cells are primed by the fusion cells to induce MHC class I-dependent lysis of autologous breast tumor cells. These findings demonstrate that fusions of human breast cancer cells and DCs activate T cell responses against autologous tumors.

Entities:  

Mesh:

Year:  2000        PMID: 10688917      PMCID: PMC15995          DOI: 10.1073/pnas.050587197

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

Review 1.  The dendritic cell system and its role in immunogenicity.

Authors:  R M Steinman
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

2.  Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors.

Authors:  D Kufe; G Inghirami; M Abe; D Hayes; H Justi-Wheeler; J Schlom
Journal:  Hybridoma       Date:  1984

3.  The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro.

Authors:  J W Young; L Koulova; S A Soergel; E A Clark; R M Steinman; B Dupont
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

4.  Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.

Authors:  F J Hsu; C Benike; F Fagnoni; T M Liles; D Czerwinski; B Taidi; E G Engleman; R Levy
Journal:  Nat Med       Date:  1996-01       Impact factor: 53.440

5.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity.

Authors:  J I Mayordomo; T Zorina; W J Storkus; L Zitvogel; C Celluzzi; L D Falo; C J Melief; S T Ildstad; W M Kast; A B Deleo
Journal:  Nat Med       Date:  1995-12       Impact factor: 53.440

6.  The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro.

Authors:  K Inaba; M Witmer-Pack; M Inaba; K S Hathcock; H Sakuta; M Azuma; H Yagita; K Okumura; P S Linsley; S Ikehara; S Muramatsu; R J Hodes; R M Steinman
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

7.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

Authors:  L Zitvogel; J I Mayordomo; T Tjandrawan; A B DeLeo; M R Clarke; M T Lotze; W J Storkus
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

8.  Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.

Authors:  C M Celluzzi; J I Mayordomo; W J Storkus; M T Lotze; L D Falo
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

9.  B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells.

Authors:  C Caux; B Vanbervliet; C Massacrier; M Azuma; K Okumura; L L Lanier; J Banchereau
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

10.  Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.

Authors:  P Paglia; C Chiodoni; M Rodolfo; M P Colombo
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  44 in total

1.  Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo.

Authors:  Jin-Kun Zhang; Jun Li; Juan Zhang; Hai-Bin Chen; Su-Biao Chen
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

Review 2.  In situ dendritic cell vaccination for the treatment of glioma and literature review.

Authors:  Ming Li; Shuangyin Han; Xiwen Shi
Journal:  Tumour Biol       Date:  2015-08-29

3.  Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.

Authors:  Jacalyn Rosenblatt; Baldev Vasir; Lynne Uhl; Simona Blotta; Claire Macnamara; Poorvi Somaiya; Zekui Wu; Robin Joyce; James D Levine; Dilani Dombagoda; Yan Emily Yuan; Karen Francoeur; Donna Fitzgerald; Paul Richardson; Edie Weller; Kenneth Anderson; Donald Kufe; Nikhil Munshi; David Avigan
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

4.  Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization.

Authors:  Shuang-Jian Qiu; Lina Lu; Chunping Qiao; LiangFu Wang; Zhong Wang; Xiao Xiao; Shiguang Qian; John J Fung; Sheng-Long Ye; C Andrew Bonham
Journal:  J Cancer Res Clin Oncol       Date:  2005-04-08       Impact factor: 4.553

Review 5.  Exploiting dendritic cells for active immunotherapy of cancer and chronic infections.

Authors:  David W O'Neill; Nina Bhardwaj
Journal:  Mol Biotechnol       Date:  2007-06       Impact factor: 2.695

6.  Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential.

Authors:  Ozcan Met; Jens Eriksen; Inge Marie Svane
Journal:  Mol Biotechnol       Date:  2008-06-10       Impact factor: 2.695

7.  Run-in phase III trial design with pharmacodynamics predictive biomarkers.

Authors:  Fangxin Hong; Richard Simon
Journal:  J Natl Cancer Inst       Date:  2013-10-04       Impact factor: 13.506

8.  Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

Authors:  Maria R Parkhurst; Cormac DePan; John P Riley; Steven A Rosenberg; Suyu Shu
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

9.  Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells.

Authors:  Baldev Vasir; Zekui Wu; Keith Crawford; Jacalyn Rosenblatt; Corrine Zarwan; Adam Bissonnette; Donald Kufe; David Avigan
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.

Authors:  Dajing Xia; Shu Zheng; Weiping Zhang; Long He; Qingqing Wang; Jianping Pan; Lihuang Zhang; Jianli Wang; Xuetao Cao
Journal:  J Mol Med (Berl)       Date:  2003-08-21       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.